Correction: The insoluble excretion of multi-matrix system mesalazine preparations in patients with ulcerative colitis

Correction: The insoluble excretion of multi-matrix system mesalazine preparations in patients with ulcerative colitis

Bibliographic Details
Main Authors:	Yuichiro Ohtaki, Kan Uchiyama, Hirotaka Kamiya, Eri Moriizumi, Moe Yamada, Yuma Aoki, Toshimune Watanabe, Sachie Kiryu, Shizuka Suzuki, Yoshihiro Matsumoto, Zensho Ito, Toshifumi Ohkusa, Shigeo Koido, Masayuki Saruta
Format:	Article
Language:	English
Published:	BMC 2023-02-01
Series:	BMC Gastroenterology
Online Access:	https://doi.org/10.1186/s12876-022-02608-z

Similar Items

Analysis of the NUDT15 gene and metabolites of azathioprine in Japanese patients with inflammatory bowel disease
by: Shizuka Suzuki, et al.
Published: (2023-07-01)

Metagenomic analyses of the gut microbiota associated with colorectal adenoma.
by: Keisuke Saito, et al.
Published: (2019-01-01)

Dysbiosis of the Fecal and Biliary Microbiota in Biliary Tract Cancer
by: Zensho Ito, et al.
Published: (2022-10-01)

Comparison of efficacy of multimatrix mesalazine 4.8 g/day once-daily with other high-dose mesalazine in active ulcerative colitis: a randomized, double-blind study
by: Haruhiko Ogata, et al.
Published: (2017-07-01)

MESALAZINE PLACE IN THERAPY OF ULCERATIVE COLITIS
by: I. G. Bakulin, et al.
Published: (2017-11-01)

Encapsulation of Hydrocortisone and Mesalazine in Zein Microparticles
by: Peter J. Halley, et al.
Published: (2013-05-01)

Comparative evaluation of the effectiveness of monotherapy of ulcerative colitis with mesalazine MMX and combination therapy with non-prolonged mesalazines with rectal forms
by: O. V. Knyazev, et al.
Published: (2022-08-01)

Efficacy of mesalazine at ulcerative colitis with nutritional failure
by: A. V. Korolyov, et al.
Published: (2024-03-01)

Nanoparticles Obtained from Zein for Encapsulation of Mesalazine
by: Izabela Borges C. Lima, et al.
Published: (2022-12-01)

Acetylated cashew gum nanoparticles for mesalazine delivery
by: Izabela Lima, et al.
Published: (2023-06-01)

Effects of mesalazine enemas on lymphoid follicular proctitis
by: Zhipeng Liu, et al.
Published: (2018-09-01)

Analysis of clinical characteristics of mesalazine-induced cardiotoxicity
by: Junyu Chen, et al.
Published: (2022-09-01)

Synthesis, Characterization, and Antibacterial Activity of Some Mesalazine Derivatives
by: Ekhlas Qanber Jasim, et al.
Published: (2023-07-01)

Insights into Mesalazine Use in Clinical Practice of Young Gastroenterologists
by: Olga Maria Nardone, et al.
Published: (2023-03-01)

Mesalazine-induced myopericarditis in a patient with ulcerative colitis
by: Jalal Asadi, et al.
Published: (2017-12-01)

An In Vitro Study Evaluating the Safety of Mesalazine on Human Nasoepithelial Cells
by: William Murphy, et al.
Published: (2024-02-01)

Prospects of MMX Mesalazine in Routine Outpatient Treatment of Ulcerative Colitis
by: Yu. P. Uspenskiy, et al.
Published: (2022-03-01)

Evaluation of the efficacy of MMX mesalazine therapy for moderate ulcerative colitis
by: O. V. Knyazev, et al.
Published: (2021-05-01)

Drug-Induced Lung Disease (Organizing Pneumonia) Associated with Mesalazine
by: E. V. Smirnova, et al.
Published: (2022-02-01)

Fouron : insoluble
by: Kas Deprez, et al.
Published: (1987-05-01)

John Dumbleton on Insolubles: An Edition of an Epitome of His Solution to Insolubles
by: Barbara Bartocci, et al.
Published: (2022-07-01)

What is the optimal dosage of mesalazine to maintain remission in patients with ulcerative colitis?
by: Travis, S
Published: (2005)

Investigation of mesalazine as an antifibrotic drug following myocardial infarction in male mice
by: Stephan R. Künzel, et al.
Published: (2023-09-01)

Efficacy of oral prolonged‐release mesalazine in moderately active ulcerative colitis
by: Kristine Paridaens, et al.
Published: (2023-07-01)

Complex compounds of mesalazine with cyclodextrins and the prospect of their application in the ulcer disease treatment
by: Borisova N. S., et al.
Published: (2023-01-01)

An economic evaluation comparing concomitant oral and topical mesalazine versus oral mesalazine alone in mild-to-moderately active ulcerative colitis based on results from randomised controlled trial.
by: Connolly, M, et al.
Published: (2009)

Editorial: Gut microbiota and gastrointestinal disorders
by: Abbas Yadegar, et al.
Published: (2022-11-01)

Systematic review: the potential influence of mesalazine formulation on maintenance of remission in Crohn's disease.
by: Steinhart, A, et al.
Published: (2007)

Green Spectrophotometric Method for Determination of Mesalazine Drug by Oxidative Coupling Reaction with Phenoxazine
by: Abdussamed Mohammed Ali Saeed, et al.
Published: (2023-12-01)

Physicochemical Compatibility Investigation of Mesalazine and Folic Acid Using Chromatographic and Thermoanalytical Techniques
by: Mario-Livio Jeličić, et al.
Published: (2020-08-01)

Molecular Mechanisms of the Antitumor Effects of Mesalazine and Its Preventive Potential in Colorectal Cancer
by: Joanna Słoka, et al.
Published: (2023-06-01)

The effectiveness of mesalazine therapy of ulcerative colitis of moderate severity in real clinical practice
by: O. V. Knyazev, et al.
Published: (2019-10-01)

Effectiveness of treatment of moderate ulcerative colitis with prolonged mesalazine in real clinical practice
by: O. V. Knyazev, et al.
Published: (2021-10-01)

The efficacy of mesalazine on nonspecific terminal ileal ulcers: A randomized controlled trial
by: Junrong Li, et al.
Published: (2022-09-01)

Effect of intra-abdominally administered mesalazine (5-aminosalicylic acid) in experimental peritonitis
by: Aziz Şener, et al.
Published: (2018-09-01)

The Effect of Mesalazine on Pain Management in Patients with Diarrhea-Predominant Irritable Bowel Syndrome
by: M Khosravi, et al.
Published: (2022-03-01)

Gastrointestinal disorders and intestinal bacteria: Advances in research and applications in therapy
by: Toshifumi Ohkusa, et al.
Published: (2023-02-01)

Hot topics on fecal microbiota transplantation for the treatment of inflammatory bowel disease
by: Xiaochen Zhang, et al.
Published: (2022-12-01)

Water-insoluble drug formulation /
by: Liu, Rong, 1956-
Published: (2008)

Pozzolnnic activity and insoluble residue
by: F.O. Anderegg
Published: (1950-11-01)